T-VEC in Combination with Ipilmumab for Melanoma Treatment
Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the rationale behind a phase Ib study to evaluate the efficacy and safety of T-VEC and ipilimumab in previously untreated, unresected stage IIIB-IV melanoma
Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the rationale behind a phase Ib study to evaluate the efficacy and safety of T-VEC and ipilimumab in previously untreated, unresected stage IIIB-IV melanoma.
Clinical Pearls:
- Researchers used T-VEC, an oncolytic virus, because of previous positive data.
- T-VEC can unleash multiple antigens from the lysine tumor regardless of the tumor genotype. These antigens will then be presented to the dendritic cells, which are driven to the event from T-VEC.
- These dendritic cells teach T cells to start killing the tumor locally and hopefully throughout the body. In order to augment a response throughout the body, ipilimumab is used.
- Although ipilimumab helps 25% of patients live longer and have long durable responses, sometimes these responses are slow. Adding T-VEC may help speed up the responses in a safe manner.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
